Background/Aims: Cilostazol has been previously demonstrated to inhibit IL-23 production in human synovial macrophages via a RhoA/ROCK-dependent pathway. However, whether cilostazol affects IL-23 production in human dendritic cells remains largely unknown. The present study was designed to investigate this question and elucidate the possible underlying mechanisms. Methods: Human monocyte-derived dendritic cells (mo-DCs) were pretreated with or without cilostazol and then incubated with zymosan. Enzyme-linked immunosorbent assay (ELISA) and real time PCR analyses were used to measure IL-23 protein expression and RNA levels, respectively, whereas Western blotting was used to measure the expression and phosphorylation level of AMPK. Results: Our results demonstrated that cilostazol suppressed zymosan-induced IL-23 protein production in a concentration dependent manner without affecting dendritic cell viability. In addition, it was found that cilostazol suppressed the expression of the p19 and p40 subunits of IL-23. Moreover, cilostazol mimicked the effect of the AMPK agonist A-769662, as demonstrated by the fact that IL-23 production was also inhibited by A-769662, and the effect of cilostazol on IL-23 production was blocked by the AMPK antagonist Compound C. More importantly, Western blotting demonstrated that cilostazol led to an increased phosphorylation of AMPK. Conclusion: Collectively, our data suggest that cilostazol inhibits the production of IL-23 in human mo-DCs, potentially via the activation of AMPK. This suggests that cilostazol could be an effective anti-inflammatory agent in IL-23-and dendritic cell-related diseases.
Introduction
Cilostazol, a phosphodiesterase type 3 (PDE3) inhibitor, has been widely used to alleviate intermittent claudication in individuals with peripheral vascular disease [1] . Its mechanism of action has been attributed to its vasodilatory effect and the inhibition of platelet aggregation [2] . By acting through PDE3, cilostazol suppresses the degradation of cAMP, resulting in increased intracellular cAMP concentrations and corresponding downstream events. While the inhibition of platelet aggregation by cilostazol has been accepted for decades, its modulatory role in the inflammatory cascade warrants further study.
Dendritic cells (DCs), important antigen presenting cells, act as a bridge between innate and adaptive immune responses [3, 4] . When exposed to microbial infections, dendritic cells rapidly secrete IL-23 [5, 6] . IL-23 is a member of the IL-12 superfamily, which is a heterodimer composed of IL-23 p19 and p40. IL-23 is a proinflammatory cytokine that is known to be produced by activated antigen-presenting cells, including DCs and macrophages. In addition, IL-23 has been demonstrated to play important immune regulatory roles in the body, including inducing T helper 17 cells (Th17) differentiation and promoting IL-22 production. Studies showed that IL-23 is involved in many autoimmune diseases, such as rheumatoid arthritis (RA) [7] , and regulation of IL-23 pathway was demonstrated to play a role in the improvement of psoriasis [8] . More importantly, Subramanian et al. demonstrated IL-23's involvement in the development of cardiovascular diseases, such as atherosclerosis [9] and Hu et al. demonstrated IL-23's involvement in myocardial ischemia and reperfusion (I/R) injury [10] . Therefore, IL-23 may serve as a pivotal target for treating inflammatory and cardiovascular diseases.
Many studies [11] [12] [13] [14] [15] [16] have focused on the pleiotropic effects of cilostazol (beyond its anti-platelet effect); however, the mechanisms underlying the anti-inflammatory effect of cilostazol are not always the same and depend on the cell type involved. In view of the important role of IL-23 in inflammatory diseases and cardiovascular diseases, it is crucial to investigate the effect of cilostazol on IL-23 production. Only one study has demonstrated that cilostazol inhibits IL-23 production in human synovial macrophages [16] , but there has not been any investigation of cilostazol's effect on IL-23 production in DCs. Given that DCs are important IL-23-producing cells in humans, we present our findings on the effects of cilostazol on IL-23 production in human mo-DCs and then explore the possible underlying mechanisms.
Materials and Methods

Reagents and Antibodies
The following reagents were used: zymosan (Sigma-Aldrich), cilostazol (Sigma-Aldrich), DMSO (SigmaAldrich), A-769662 (Santa Cruz) and Compound C (Medchemexpress). AMPK (adenosine 5'-monophosphate (AMP)-activated protein kinase) and p-AMPK antibodies were from Cell Signaling Technology. Tubulin mouse monoclonal antibodies were from Beyotime Biotechnology (Shanghai, China). Human GM-CSF and IL-4 were from Peprotech Inc.
Cell Cultures and Transfection
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy human donors and were isolated via Ficoll-Paque density gradient centrifugation. PBMCs were resuspended in RPMI 1640 medium containing 20 mM HEPES, 100 U/ml penicillin/streptomycin, 2 mM L-glutamine, 1% nonessential amino acids, and 10% heat-inactivated fetal bovine serum (Gibco, USA). Cells were then plated in 10-cm dishes for 2 h in an incubator with 5% CO 2 , and monocytes were obtained by discarding the non-adherent cells. The purity and viability of CD14+ cells were consistently over 80% and 94%, respectively, as we have previously reported [17] . Mo-DCs were obtained by a 5-d culture of monocytes in medium composed of 50 ng/mL GM-CSF (Peprotech) and 12 ng/mL IL-4 (Peprotech) as previously reported [18] . Fresh complete medium was replaced in every 3 days. All blood samples from healthy donors were obtained in accordance with the National Institutes of Health approved institutional review board protocols.
Cells from the human embryonic kidney cell line HEK293T were incubated with DMEM medium containing 10% fetal bovine serum, 2mM L-Glutamine and 100 U/ml penicillin/streptomycin in an incubator with CO 2 at 37°C. HEK293T cells were seeded in 96-well plates overnight and were transfected according to the manufacturer's instructions.
Cell Counting and Viability
To determine whether cilostazol affects mo-DC cell counts and viability, the Guava ViaCount Assay was performed per the manufacturer's instructions.
Dual-Luciferase Reporter Assay
A luciferase assay was performed as previously reported [17] . In brief, the human IL23A (1 kbp fragment) was amplified from human genomic DNA and ligated into the pGL4.20 vector (Promega). HEK293T cells were seeded in 96-well plates overnight and then transfected with reporter plasmids encoding IL23A and plasmids for MyD88 using Lipofectamine 2000 (Invitrogen). Renilla luciferase expression vectors, pRL-TK (Promega), were cotransfected as internal controls. To investigate the role of cilostazol on the MyD88-induced (20 ng) upregulation of IL23A promoter activity, different doses of cilostazol (0-40 µM) or the solvent control (DMSO) were added as pretreatments at the beginning of transfection. Cell lysates were collected 40 h later, and luciferase activity was detected as previously described [17] . Luciferase units for IL23A were divided by the values for the renilla control.
ELISA Levels of IL-23 in supernatants harvested from human mo-DCs were measured using an ELISA kit for human IL-23 from Mabtech according to the manufacturer's instructions.
Real-Time PCR
Total RNA was extracted from human mo-DCs using TRIzol reagents (Invitrogen, San Diego, CA) according to the manufacturer's instructions. IL-23 p19 and p40 gene expression levels were detected via the SYBR Green-based real-time PCR technique. The following primers specific for p19, p40 and EF1α were shown as follows: for p19, sense 5'-CTC TGC TCC CTG ATA GCCCT-3' and antisense 5'-TGC GAA GGA TTT TGA AGCGG-3'; for p40, sense 5'-GGA GAG TCT GCC CAT TGAGG-3' and antisense 5'-TCT TGG GTG GGT CAG GTTTG-3'; for EF1α, sense 5'-ATA TGG TTC CTG GCA AGCCC-3' and antisense 5'-GTG GGG TGG CAG GTA TTAGG-3'. PCRs were performed on a Corbett 65H0 machine (Corbett Research, Sidney, Australia) with the following cycling conditions: 95°C for 15 s and 60°C for 1 min, for 40 cycles. The housekeeping gene EF1α was used as the internal control. The quantification data were analyzed by Rotor-Gene Q Series Software 1.7 (Corbett Research, Sidney, Australia).
Western Blotting
Western blotting was performed as previously described [19] . Briefly, human mo-DCs were lysed in a buffer (1 mM each: antipain, benzamidine, leupeptin, pepstatin A, and phenylmethyl sulfonyl fluoride (PMSF), with 1% sodium dodecyl sulphate (SDS), and 5 mM ethylene diamine tetraacetic acid (EDTA)) to obtain the total protein. Proteins (30 µg protein/lane) were electrophoresed on an 8% SDS-polyacrylamide gel and transferred to nitrocellulose membranes (Pall Corporation, Ann Arbor, MI). After being blocked with BSA (3% wt/vol) in tris-buffered saline containing Tween 20 (0.5% vol/vol; TBS-T) for 1 h at room temperature, the membranes were incubated with antibodies against p-AMPK (1:1000), AMPK (1:1000) and tubulin (1:3000) overnight at 4°C. After rinsing three times, the blots were then incubated with the corresponding secondary antibodies at room temperature for 1 h. Signals of bands were visualized by an enhanced chemiluminescence (ECL) detection system (Bio-Rad, Hercules, CA) and quantified using Quantity One Software (Bio-Rad).
Statistical Analysis
All data were presented as means ± SEM. Significance of results was determined by one way ANOVA followed by Tukey post hoc testing using GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). P value of less than 0.05 was accepted as statistically significant.
Results
Cilostazol suppressed zymosan-induced IL-23 production in mo-DCs
To determine the effect of cilostazol on IL-23 production in mo-DCs, mo-DCs were pretreated with cilostazol (10-40 μM) for 4 h, and were then stimulated with zymosan (20 µg/ml) for 24 h. ELISA data demonstrate that zymosan elicited IL-23 production, and cilostazol suppressed zymosan-induced IL-23 production in a concentration dependent fashion (Fig. 1A) . In addition, as shown in Fig. 1B and 1C , the viability and number of mo-DCs were not obviously affected by the cilostazol treatment, which indicates that the inhibitory effect of cilostazol on IL-23 production was not due to negative effects on the viability and number of mo-DCs. Collectively, these data indicate that cilostazol inhibits the production of IL-23 at the protein level in human mo-DCs.
Cilostazol suppressed IL-23 p19 and p40 expression IL-23 is a heterodimer composed of the subunits p19 and p40. RT-PCR analyses were performed to determine whether cilostazol affects IL-23 production at the transcription level. As shown in Fig. 2 , there was an up-regulation of both p19 and p40 subunit expression upon zymosan stimulation. More importantly, it was demonstrated that cilostazol exhibited a significant inhibitory effect on the subunits p19 and p40 (Fig. 2 ) that was not demonstrated in the solvent control DMSO. These results suggest that cilostazol inhibits IL-23 production at the RNA level in human mo-DCs. In combination with the aforementioned ELISA data, these results indicate that cilostazol inhibits IL-23 production, resulting in decreased IL-23 protein and RNA levels in human mo-DCs.
Cilostazol inhibited MyD88-induced IL23A transcriptional activity
Luciferase reporter assay was utilized to determine the effect of cilostazol on IL23A transcriptional activity in HEK293T cells. As shown in Fig. 3, IL23A promoter activity was * P < 0.05 vs. zymosan alone, ** P < 0.01 vs. zymosan alone, # P < 0.05 vs. cilostazol plus zymosan treatment. [20, 21] . Thus, we aimed to clarify whether the inhibitory effect of cilostazol on IL-23 production by mo-DCs was mediated by AMPK by treating cells with an AMPK agonist (A-769662) and an AMPK antagonist (Compound C). As shown in Fig. 4 , A-769662 acted in a concentration dependent manner to suppress the production of IL-23 in a manner similar to that of cilostazol. More importantly, Compound C was able to block the effect of cilostazol (Fig. 4) . The present study strongly suggests that cilostazol exerts its inhibitory effect on IL-23 production in human mo-DCs, at least partially, via an AMPK-dependent pathway.
Cilostazol promoted the phosphorylation level of AMPK in mo-DCs upon zymosan stimulation
The aforementioned results indirectly indicate that the inhibitory effect of cilostazol on IL-23 is related to the AMPK pathway. To further clarify the underlying mechanisms, we directly measured the expression and phosphorylation of AMPK. As shown in Fig. 5 , cilostazol effectively promoted the phosphorylation of AMPK in mo-DCs, indicating that cilostazol may suppress the IL-23 production in mo-DCs via the activation of AMPK.
Discussion
In the present study, treatment with cilostazol was demonstrated to suppress IL-23 production via the activation of AMPK in human mo-DCs. This conclusion is based on the following observations: 1) cilostazol inhibited zymosan-induced IL-23 production at both the protein and RNA levels, as well as MyD88-induced IL23A promoter activity; 2) cilostazol mimicked the effect of an AMPK agonist (A-769662) on IL-23 production, and the effect of cilostazol on IL-23 production can be blocked by an AMPK antagonist (Compound C); and 3) cilostazol promoted the phosphorylation of AMPK.
DCs, important IL-23 producing cells in the human body, play a pivotal role in innate and adaptive immune responses [3, 4] and have received attention as promising targets for treating coronary heart disease and other cardiovascular diseases [22, 23] . In the present study, we have demonstrated for the first time that cilostazol suppresses IL-23 production in human mo-DCs, suggesting that cilostazol is able to regulate DC function. However whether cilostazol could be used as a potential drug to target DCs warrants further study. Some reports have shown that the effect of cilostazol is associated with the activation of the AMPK pathway, and this effect has been validated in various models [20, 21, 24, 25] . Furthermore, AMPK has been suggested to play an important role in TLRs-induced IL-23 production [26] . However, it remains unclear whether the inhibitory effect of cilostazol on IL-23 production is mediated via an AMPK-dependent pathway in human mo-DCs. In the present study, it was observed that cilostazol had the same effect as an AMPK agonist (A-769662) on IL-23 production, and the effect of cilostazol on IL-23 production was blocked by an AMPK antagonist (Compound C), suggesting that the underlying mechanism of the cilostazol-induced inhibitory effect on IL-23 was mediated via an AMPK pathway. Moreover, the Western blotting analysis showed that cilostazol promoted the phosphorylation of AMPK in mo-DCs. Collectively, our data demonstrate that cilostazol suppresses IL-23 production via the activation of an AMPK-dependent pathway in human mo-DCs. However, in the present study, we used human IL-23A gene promoter (1 kb fragment), which includes κB, C/EBPβ, ATF2 [27, 28] . It has been reported that AMPK-IKβα-NFκB signaling is involved in sildenafil's anti-inflammatory effects [29] . In addition, it has been reported that AMPK could suppressed C/EBPβ expression [30, 31] . As to ATF2, it has been reported that AMPK could phosphorylate ATF1, but not ATF2 [32] . And the downstream transcription factors affected by AMPK, which contribute to IL-23 suppression, need to be further characterized.
While our results are the first to demonstrate cilostazol's anti-inflammatory properties in human mo-DCs, numerous studies have reported these properties in other cell-types. Shin et al. found that cilostazol suppresses NAD(P)H oxidase-dependent superoxide formation and inflammatory cytokine production in HUVECs (human umbilical vein endothelial cells) [11] . In addition, it has been reported that cilostazol inhibits the expression of adhesion molecules and chemokine release by HUVECs [12] , indicating that cilostazol has an anti-inflammatory effect on HUVECs. Furthermore, it has been demonstrated that the anti-inflammatory effects of cilostazol may result from cAMP-dependent protein kinase activation-mediated inhibition of NF-κB gene transcription [13] . Cilostazol has also been shown to inhibit IFN-α and TNF-α production from plasmacytoid dendritic cells in a dosedependent manner [14] . In addition, cilostazol has been reported to suppress TNF-α and IL-1β production in synovial macrophages from RA patients via inhibition of TLR4/MyD88/ NF-κB signaling pathways [15] . Moreover, cilostazol inhibits TLR2-induced IL-23 production in human synovial macrophages by suppressing the RhoA pathway via a cAMP-dependent pathway [16] . These studies suggest that cilostazol serves as a potent anti-inflammatory drug with immunomodulatory properties, and our study further demonstrates the pleiotropic effects of cilostazol.
This study does have some limitations. In the present study, zymosan stimulation was demonstrated to be a strong inducer of IL-23 production in mo-DCs. It has been demonstrated that zymosan triggers signal transduction through dectin-1 and TLR2 and that it activates signal cascades, including ERK and p38 MAPK, and these proteins are involved in zymosan-induced signaling pathways [27] . It remains unclear whether cilostazol suppresses IL-23 production in mo-DCs by regulating the phosphorylation level of ERK and p38 MAPK after a zymosan challenge. Signaling pathways regarding IL-23 production in mo-DCs are interconnected, so the present study cannot preclude the possibility that other mechanisms may be involved. In addition, the concentration of cilostazol used in the present study was far greater than its serum concentrations (approximately 2 μM) in the human body. However, considering the intestinal absorption of cilostazol, it can be posited that local serum cilostazol concentrations in the small intestine are obviously far greater than the blood concentration in the body. More importantly, it has been validated by Akiyama et al. that the local concentration in the stomach, small intestine and liver can be 21, 4 and 4 times higher than the blood concentration [33] . Based on this observation, it seems that the roles of cilostazol in intestinal inflammation should be considered and carefully evaluated in the future. This raises the question as to whether cilostazol influences IL-23 production in clinical practice. Future clinical studies are warranted to clarify whether the beneficial effect of cilostazol in clinic practice may be related to its inhibitory effect on IL-23 production. In addition, the inhibition of IL-23 protein by cilostazol is higher than the inhibition of both p19 and p40 gene expression. This phenomenon can be explained by the following
